Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Insulin dependent type 1 diabetes mellitus diagnosed within the previous 3 months at time of screening~* Fasting C-peptide level at time of screening above 0.1 nmol/L~* Elevated GAD65 antibodies (GADA) at time of screening~* Male and female patients between 10 and 20 years of age~Main Exclusion Criteria:~* Treatment with immunosuppressants or any anti-diabetic medications other than insulin~* A history of certain diseases or conditions (e.g. anemia, HIV, hepatitis, epilepsy, head trauma, neurological diseases or cerebrovascular accident, alcohol or drug abuse etc)~* Treatment with any vaccine within 1 month prior to planned first Diamyd dose or planned treatment with vaccine up to 2 months after the last injection with Diamyd, excluding the influenza vaccine~* Participation in other clinical trials with a new chemical entity within the previous 3 months~* Pregnancy or planned pregnancy within 1 year after the last Diamyd dose~* Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on days 90 and 270.
- B (Type: ACTIVE_COMPARATOR): This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on days 90 and 270.
- C (Type: PLACEBO_COMPARATOR): This arm will receive 4 injections of placebo, 1 each on days 1, 30, 90 and 270.

Based on this trial design, predict the completion outcome and termination type (if applicable).